IPO Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Christer Rosen, Chairman and Chief Executive Officer, and Alison Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the company’s treatments for neuroinflammation and rare diseases through JOTROL, its patented resveratrol delivery platform. They also talked about the company’s clinical pipeline with $50B+ combined market opportunities, and more.
Watch the full interview below, or click HERE:
About Christer Rosen
Mr. Rosén is Co-Founder, Chief Executive Officer and Chairman of the Board of Directors of Jupiter Neurosciences, Inc. since January 1, 2016. Mr. Rosén is a serial entrepreneur and has started several businesses in various industries. From 1997 through May 2015, Mr. Rosén founded and served as the Chief Executive Officer and Chairman of EffRx Pharmaceuticals. At EffRx Mr. Rosén, together with an experiences pharmaceutical team, invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto. Binosto is distributed in several parts of the world and gave Mr. Rosén a full insight in all the aspects of pharmaceutical development, regulatory paths and worldwide distribution. EffRx was acquired in 2023 by Abiogen SA.
Mr. Rosén is a graduate of Malmo Trade Schools/Lund University, Sweden, with a degree in Computer Sciences in 1971.
About Alison Silva
Alison D. Silva is the President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). She is also the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc., formerly Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company’s focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.
Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison obtained her undergraduate degree from Clark University and her graduate degree from the University of Massachusetts Medical Center.
About Jupiter Neurosciences, Inc. (Nasdaq: JUNS)
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, including indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
READ MORE
5th Palm Beach CorpGov Forum Highlights & Look Ahead
Register for our weekly newsletter HERE
Contact:
Editor@IPO-Edge.com
Click HERE to follow us on LinkedIn
